{
  "url": "https://openlegislation.uk/eu-decision-2013-701/annex-I/division-1",
  "json_url": "https://openlegislation.uk/eu-decision-2013-701/annex-I/division-1.json",
  "legislation": "eudn/2013/701",
  "legislation_title": "Commission Implementing Decision of 22 November 2013 on setting up the Biobanks and Biomolecular Resources Research Infrastructure Consortium (BBMRI-ERIC) as a European Research Infrastructure Consortium (2013/701/EU)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2013-701",
  "path": "annex/I/division/1",
  "kind": "division",
  "number": null,
  "heading": null,
  "text": "THE KINGDOM OF BELGIUM,\nTHE CZECH REPUBLIC,\nTHE FEDERAL REPUBLIC OF GERMANY,\nTHE REPUBLIC OF ESTONIA,\nTHE HELLENIC REPUBLIC,\nTHE FRENCH REPUBLIC,\nTHE ITALIAN REPUBLIC,\nTHE REPUBLIC OF MALTA,\nTHE KINGDOM OF THE NETHERLANDS,\nTHE REPUBLIC OF AUSTRIA,\nTHE REPUBLIC OF FINLAND,\nTHE KINGDOM OF SWEDEN,\nHEREINAFTER REFERRED TO AS ‘THE MEMBERS’,\nand:\nTHE KINGDOM OF NORWAY,\nTHE REPUBLIC OF POLAND,\nTHE SWISS CONFEDERATION,\nTHE REPUBLIC OF TURKEY,\nHEREINAFTER REFERRED TO AS ‘THE OBSERVERS’.\nWHEREAS the Members are convinced that biological human samples including associated medical data and biomolecular research tools are a key resource in unravelling the interplay of genetic and environmental factors causing human diseases and impact on their outcome, identification of new biomarkers and targets for therapy as well as contributing to reduce attrition in drug discovery and development.\nWHEREAS the biomolecular resources include antibody and affinity binder collections, cell lines, clone collections, siRNA libraries and other research tools needed for analysis of biobanked samples. Also repositories of model organisms are considered biomolecular resources when relevant to human diseases.\nWHEREAS the pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) will build on existing sample collections, resources, technologies and expertise, which will be specifically complemented with innovative components and properly embedded into European scientific, ethical, legal and societal frameworks.\nCONSIDERING that the Members seek to increase the scientific excellence and efficacy of European research in the biomedical sciences as well as to expand and secure competitiveness of European research and industry in a global context and to attract investments in pharmaceutical and biomedical research facilities, by establishing the Biobanking and Biomolecular Research Infrastructure — European Research Infrastructure Consortium —hereinafter referred to as ‘BBMRI-ERIC’.\nEMPHASISING the Members’ commitment to the Charter of Fundamental Rights of the European Union as proclaimed by the Council and European Commission in Nice in December 2000 and in particular European and national data protection legislation.\nWHEREAS the Members request the European Commission to set up BBMRI according to the ERIC Regulation as a European Research Infrastructure Consortium (ERIC) legal entity.\nHAVE AGREED AS FOLLOWS:",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2013/701/annex/I/division/1",
    "retrieved_at": "2026-11-01T15:14:57.296195+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}